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Mineral Bone Disorder
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Abstract
Introduction: Noninvasive measures of bone activity include intact parathyroid hormone (iPTH) and
bone-speciﬁc alkaline phosphatase (BSAP). Whether BSAP measurement alone or in combination with
other biochemical data provides more reliable information about bone turnover than iPTH alone in African
Americans on hemodialysis is unknown. Methods: This cross-sectional study aimed to determine the
optimal predictor and cutoff points for BSAP, iPTH, calcium and phosphorus in classifying bone biopsy
ﬁndings. Forty-three African American hemodialysis patients were available for analysis. Biochemical data
on the day of biopsy across a spectrum of qualitative histologic bone features were compared. Classiﬁcation and regression tree analysis was used to determine both the optimal predictor and cutoff points for
BSAP, iPTH, calcium and phosphorus in identifying bone turnover status. Findings: Seven subjects had
adynamic disease, 31 had mild/moderate hyperparathyroid bone features, and ﬁve had severe hyperparathyroid bone disease. BSAP was the optimal predictor of bone biopsy with a cutoff point of 22 ng/mL. Calcium and phosphorus had no predictive value. At BSAP  22 ng/mL, subjects had either adynamic bone
disease or mild/moderate hyperparathyroid bone disease but iPTH was not useful in further classifying
biopsy ﬁndings. When BSAP was >22 ng/mL, subjects had either mild/moderate or severe hyperparathyroid bone disease, and iPTH was useful in further classifying biopsy ﬁndings. With BSAP > 22 ng/mL and
iPTH < 726 pg/mL, all subjects had mild/moderate bone turnover features. Discussion: Compared to
iPTH, BSAP was shown to be the optimal predictor of biopsy ﬁndings with an optimal cutoff at 22 ng/mL.
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INTRODUCTION
Renal bone disease manifests in derangements in bone
histologic findings such as abnormalities in bone turnover, mineralization, and volume.1 Bone histology is the
“gold standard” for definitive diagnosis of the osteodystrophic lesion; however, because it is a painful, costly
procedure, nephrologists rely mainly on intact parathyroid hormone (iPTH) measurements to predict bone histology and guide treatment. The 2009 Kidney Disease
Improving Global Outcomes (KDIGO) Clinical Practice
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Guidelines for Bone Metabolism and Disease in Chronic
Kidney Disease state that measurements of iPTH and
bone-specific alkaline phosphatase (BSAP) may be used
to evaluate bone disease, because high or low values predict underlying bone turnover. KDIGO recommends
maintaining iPTH approximately two to nine times the
upper limit of normal, but no specific target value or
range has been proposed for BSAP.2 Although iPTH is
used more often as a marker of bone turnover in clinical
practice, use of BSAP has been suggested recently because
of its lower biologic variability and better clinical outcome
predictability.3–5
Ethnicity has an important role in many aspects of
bone and mineral metabolism including the relationship
between markers of bone turnover and bone histology.
Serum iPTH is higher in African Americans irrespective of
the type of bone remodeling. Of several studies that compared BSAP and iPTH with bone histomorphometry, all
except one were predominantly in white patients. African
Americans in particular have a lower bone turnover than
whites across a wide range of iPTH levels,6 a condition
that should not be taken lightly given the association of
low turnover bone disease with cardiovascular calcification7 and vertebral and hip fractures in the end-stage
renal disease population.8,9 Serum iPTH shows significant
correlations to bone formation in white patients but not
in African American patients.10 Therefore, it is important
to explore the role of markers other than iPTH for the
assessment and treatment of bone and mineral disorders
in this population.
The aim of this study was to describe the relationship
of BSAP to bone histology across the spectrum of renal
osteodystrophy in prevalent African American end-stage
renal disease patients on hemodialysis. We also aimed to
determine the optimal predictor and cutoff points for the
two noninvasive measures of bone activity, iPTH and
BSAP, in the classification of biopsy findings in African
American hemodialysis patients.

MATERIALS AND METHODS
This cross-sectional study utilized data collected for a previous study that evaluated the relationship of bone histology to iPTH and other biochemical markers.11 The
original study, conducted at three urban Detroit hemodialysis units, was approved by the Henry Ford Hospital
Institutional Review Board and informed consent was
obtained from each subject. Approval was also granted
for the current study and informed consent for this secondary analysis was waived. The study followed the Declaration of Helsinki on medical protocol and ethics.
Hemodialysis International 2017; 21:90–96

Inclusion/exclusion criteria, clinical data collection, biochemical data collection, and bone biopsy methods were
described previously.11 Briefly, bone biopsy was performed on consenting subjects within the three dialysis
units, and biochemical measurements were collected at
the time of biopsy and correlated to biopsy findings.
Qualitative histologic assessment was made using the conventional classification.12

Statistical analyses
For this study we used classification and regression tree
(CART) analysis to develop a prediction model for bone
histology.4 The prediction model was generated using
BSAP, iPTH variables, corrected calcium and phosphorus
obtained on the day of biopsy. TAP was not included in
the model given BSAP is a subset of TAP and more specific to bone than TAP. CART analysis, or binary recursive
partitioning, uses a nonparametric analytical approach
that identifies the variables most predictive of the outcome of interest and develops a predictive model for classifying future subjects. CART analysis starts with the root
node (all subjects) and then determines which variable
has the highest predictive ability. Subsequently, CART
determines the optimal cut point for this variable that partitions the population into two child nodes with explicitly
different outcomes. Every value of the predictor variable
is evaluated for its potential as a split value, and the program determines the most predictive splitter. Each child
node can then itself become a parent node that produces
its own child nodes. The process continues to classify the
subjects until no further variables of predictive importance are observed.13 CART analysis was conducted using
CART 6.0 software (Salford Systems, San Diego, CA).
Continuous variables are presented as mean with standard deviation or median with interquartile range where
appropriate. Categorical variables are expressed as frequencies and percentages. Continuous variables were
compared using one-way analysis of variance (ANOVA),
and categorical variables were compared using the Fisher
exact test. A P value of less than 0.05 was considered statistically significant.

RESULTS
A total of 43 African American hemodialysis subjects
were enrolled into the study. Qualitative bone histology
classified subjects in three groups: seven with adynamic
bone disease (ABD), 31 with mild/moderate hyperparathyroid bone disease (mild/moderate HPT) and five with
severe hyperparathyroid bone disease (severe HPT). There
91
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Figure 1 Box plots of iPTH level by bone turnover status.
Open circles indicate individual values. The median iPTH
levels were 207 pg/mL (IQR, 158–302 pg/mL; range, 41–
384 pg/mL) for ABD, 430.8 pg/mL (IQR, 268–784 pg/mL;
range, 75–2187 pg/mL) for mild/moderate HPT, and 941
pg/mL (IQR, 756–1110 pg/mL; range 75–2187 pg/mL) for
severe HPT. Abbreviations: ABD, adynamic bone disease;
iPTH, intact parathyroid hormone; HPT, hyperparathyroid
bone disease; IQR, interquartile range; mod, moderate.
[Color figure can be viewed at wileyonlinelibrary.com]

were no cases of normal bone histology, osteomalacia, or
mixed uremic renal osteodystrophy. Bone formation rate/
bone surface (mm3/cm2 per yr) was 1.66 6 0.66 in the
adynamic category, 4.53 6 1.94 in mild/mod HPT and
8.67 6 2.30 in severe HPT (normal values 1.80–3.80).
Activation frequency (yr21) was 0.27 6 0.11 in the adynamic category, 0.89 6 0.32 in mild/mod HPT and
1.67 6 0.20 in severe HPT (normal value 0.49–0.72).
Population characteristics did not differ by bone turnover status.11 Mean age was 53.7 6 11.6 years, dialysis
vintage was 40.4 6 24.5 months, 23 were male (51%), 13
were diabetic (30%) and seven had history of fractures
(16%). Most subjects were receiving intravenous vitamin
D therapy (95%) and phosphate binder therapy (93%).
Ten subjects (23%) were on calcium acetate, 28 subjects
(65%) were on sevelamer and two subjects (5%) were on
both. There was no association between bone turnover
and calcium-based binder use (adynamic 43%, mild/mod
HPT 23%, severe HPT 40%; P value 5 0.4101),
noncalcium-based binder use (adynamic 57%, mild/mod
HPT 71%, severe HPT 40%; P value 5 0.3591), average
vitamin D analogue use [pg/treatment] (adynamic 5.3 6
3.9, mild/mod HPT 4.6 6 3.0, severe HPT 3.6 6 1.3;
P value 5 0.6200) or cumulative vitamin D analogue [pg]
92

in previous 3 weeks (adynamic 41 6 27, mild/mod HPT
38 6 27, severe HPT 35 6 14; P value 5 0.918).
BSAP was positively correlated with iPTH (r 5 0.64;
P < 0.001) and TAP (r 5 0.76; P < 0.001). Correlations
between BSAP and bone histomorphometric parameters
were previously reported by Moore et al.11 Plasma
iPTH, BSAP and TAP increased with bone activity. Boxplots with individual values of iPTH, BSAP and TAP
by bone turnover status are shown in Figures 1–3,
respectively.
Using CART analysis, the strongest predictor of biopsy
findings was BSAP with a cutoff point of 22 ng/mL. Corrected calcium and phosphorus had no additional predictive value and therefore did not appear in the decision
tree. At BSAP  22 ng/mL, subjects had either ABD or
mild/moderate HPT. Serum iPTH, corrected calcium and
phosphorus were not useful in further classifying the
biopsy type. In those with BSAP > 22 ng/mL, subjects
had either mild/moderate HPT or severe HPT, and iPTH
was useful in further classifying biopsy findings. With
BSAP > 22 ng/mL and iPTH < 726 pg/mL, all subjects
had mild/moderate HPT (Figure 4).

Figure 2 Box plots of BSAP by bone turnover status. Open
circles indicate individual values. Median BSAP level was
16.2 ng/mL (IQR, 12.9–21.0 ng/mL; range, 12.6–21.5 ng/
mL) for ABD, 34.1 ng/mL (IQR, 23.2–51.5 ng/mL; range,
15.0–64.0 ng/mL) for mild/moderate HPT, and 64 ng/mL
(IQR, 63.8–64.0 ng/mL; range 46.1–64.0 ng/mL) for severe
HPT. Abbreviations: ABD, adynamic bone disease; BSAP,
bone specific alkaline phosphatase; HPT, hyperparathyroid
bone disease; IQR, interquartile range; mod, moderate.
[Color figure can be viewed at wileyonlinelibrary.com]
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Figure 3 Box plots of TAP by bone turnover status. Open
circles indicate individual values. Median TAP level was
68.0 ng/mL (IQR, 58.3–89.8 ng/mL; range, 49.0–113.0 ng/
mL) for ABD, 131.0 ng/mL (IQR, 99.3–189.0 ng/mL; range,
18.0–307.0 ng/mL) for mild/moderate HPT, and 238.0 ng/
mL (IQR, 173.5–310.0 ng/mL; range 146.0–376.0 ng/mL)
for severe HPT. Abbreviations: ABD, adynamic bone disease; TAP, total alkaline phosphatase; HPT, hyperparathyroid bone disease; IQR, interquartile range; mod, moderate.
[Color figure can be viewed at wileyonlinelibrary.com]

DISCUSSION
We used CART analysis to identify the individual cutoff
levels of BSAP and iPTH, or the particular combination of
both, that could best provide the clinician with additional
insight into determining particular bone histology in African American dialysis patients. The main finding of the
CART analysis was that BSAP was the better classification
variable and has an optimal cutoff at 22 ng/mL. The analysis also identified the values of each that correspond best
with predicted bone histology. BSAP was the primary
splitter and could clearly separate patients with ABD from
high bone turnover disease. In addition, as determined by
the CART analysis, the two tests in combination can provide a clinician with additional insight into the likelihood
of high turnover disease.
Assays for BSAP have been available for many years,
but BSAP has been largely overlooked in clinical practice
as a marker of chronic kidney disease-mineral bone disorder. BSAP is a homodimeric glycoprotein anchored to the
membrane of osteoblasts through glycosylphosphatidylinositol.14,15 It is cleaved from glycosylphosphatidylinositol and released into the circulation as a soluble
homodimer by the action phospholipases C and D.16,17
The homodimer is eliminated through hepatic degradation. It is neither filtered by the kidney nor dialyzable.18
Hemodialysis International 2017; 21:90–96

It has a relatively long half-life of 1.1–4.9 days.19,20
Many techniques have been used to measure BSAP,
including differential heat denaturation,21 electrophoresis,22 and isoelectric focusing,23 and more recently by a
number of rapid and reproducible immunoassays.24–27
However, some of these assays may exhibit a certain
degree of cross-reactivity between BSAP and liver alkaline
phosphatase. Therefore in patients with high liver alkaline phosphatase, BSAP measurements may be falsely
elevated.28
BSAP has several advantages compared to iPTH measurement. It does not accumulate with progressive loss of
glomerular filtration rate,29 has lower biological variation,3 exhibits better agreement across methods of measurement,30 and is stable ex vivo and does not require
strict preanalytical handling procedures.24
BSAP is also closely linked to clinical outcomes. It has
been shown to be a good predictor of future fracture risk
in dialysis patients31 and is strongly associated with 6month cardiovascular and non-cardiovascular mortality in
dialysis patients.32 Another study identified BSAP as an
independent predictor of all-cause mortality in men
receiving hemodialysis, whereas there was no evidence of
an association between iPTH concentration and mortality
in the same cohort.33 TAP has also been shown to be
associated with clinical outcomes. Large cohort studies
have shown that TAP is independently associated with
increased hospitalization,34 cardiovascular mortality,34,35

Figure 4 Binary recursive partitioning of BSAP and iPTH to
identify biopsy findings. All subjects with adynamic bone
disease had a BSAP  22 ng/mL. iPTH did not improve the
classification of those with BSAP  22 ng/mL. When BSAP
was > 22 ng/mL, the iPTH was useful in further classifying
biopsy findings. With BSAP > 22 ng/mL and iPTH < 726
pg/mL, all subjects had mild/moderate hyperparathyroid
bone disease. Abbreviations: BSAP, bone specific alkaline
phosphatase; iPTH, intact parathyroid hormone; mod,
moderate.
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and all-cause mortality among dialysis patients.36 Serum
TAP activity has also been shown be a predictor of coronary calcification.37 However, there is no direct evidence
as to whether the association with mortality and vascular
calcification is promoted by BSAP.iPTH alone does not
adequately predict underlying histology.2 Few studies
have compared the relationship of both BSAP and iPTH
levels to histologic bone assessment5,38–40 and BSAP
appears to be at least as closely linked to histologic
parameters as iPTH and perhaps a slightly better predictor
of low turnover bone disease in some studies. Two studies
have also described the diagnostic accuracy of BSAP for
high and low turnover bone disease.5,38 Both studies
were conducted in an era when aluminum overload was
common, and the identified thresholds for predicting
bone histology may not be applicable to modern day
hemodialysis patients. Notwithstanding this limitation,
the two studies showed that BSAP may improve the predictive value of PTH for both ABD5,38 and high turnover
disease.5
In the present study, at BSAP level > 22 ng/mL no subject had ABD. These subjects had either mild/moderate
bone disease or severe HPT. iPTH was useful in further
classifying these subjects. In those with iPTH < 726 pg/
mL, none had severe HPT. However, in those with
iPTH > 726 pg/mL, severe HPT was common. At the very
least, these cutoffs may be useful in determining those
patients at highest risk for high turnover bone disease.
Attention could be focused on decreasing bone turnover
in these patients by employing measures to allow the
iPTH to decrease to < 726 pg/mL. This may be achieved
by increasing dosages of vitamin D or its analogues and/
or by increasing dosages of phosphorus binders.
A BSAP level of  22 ng/mL identified all subjects with
either ABD or mild/moderate HPT and ruled out severe
HPT. No other laboratory measurement (calcium, phosphorus, iPTH) was useful in further differentiating ABD
from mild/moderate bone turnover disease. In these subjects, strategies to prevent ABD could be employed that
target those at highest risk for ABD; as in those with history of vascular calcification,41 hip8 and vertebral fractures.9 This could be achieved by decreasing dosages of
vitamin D or its analogues and by decreasing dosages of
calcium-based phosphorus binders or lowering of the
dialysate calcium concentration. While the results of this
study may support such an approach, there are no
randomized controlled trials that have evaluated patient
outcomes based on BSAP targeted approach. Indeed, a
prospective cohort study of incident dialysis patients in
the Netherlands showed low levels of BSAP were associated with improved survival.32 However, in contradistinc94

tion to our study, this study was conducted in Caucasians
and in patients with dialysis vintage of 12 months (versus
40.4 6 24.5 months in our study). Furthermore, the
authors contend that results may potentially differ in
long-term dialysis patients in whom suppression of bone
turnover is more common. They also acknowledge that
BSAP levels in incident dialysis patient may rather represent the general quality of care before ESRD.
The study has a few limitations. The major limitation is
the small number of patients. Furthermore, the results
could only be applicable to African American patients on
hemodialysis as there are ethnic differences in the relationship between bone turnover markers and bone histology. Finally, this study focuses on qualitative bone
histology to assess bone turnover status, without reference
to mineralization or bone volume. The KDIGO Consensus
statement recommends the use of the TMV (turnover,
mineralization, volume) classification system to assess
bone status in chronic kidney disease. This system
expands the possibilities of outcomes that describe underlying bone histology; therefore, requires a considerably
larger sample size to determine optimal cutoffs.
In conclusion, this study, together with other published
literature, advocates the use of BSAP as a marker of
chronic kidney disease-mineral bone disorder, with additional potential value in the risk stratification of African
American hemodialysis patients. The cutoffs determined
by this analysis to best predict biopsy findings warrant
further study and validation.

ACKNOWLEDGMENTS
The authors extend their gratitude to Ms. Stephanie Stebens, Sladen Library, Henry Ford Hospital, for expert
librarian assistance formatting the manuscript and to Ms.
Sarah Whitehouse, Department of Internal Medicine,
Henry Ford Hospital, for expert linguistic revision of the
manuscript.
Manuscript received February 2016; revised May 2016.

REFERENCES
1 Moe S, Drueke T, Cunningham J, et al. Definition,
evaluation, and classification of renal osteodystrophy:
A position statement from Kidney Disease: Improving
Global Outcomes (KDIGO). Kidney Int 2006; 69:1945–
1953.
2 Kidney Disease: Improving Global Outcomes (KDIGO)
CKD-MBD Work Group. KDIGO clinical practice
guideline for the diagnosis, evaluation, prevention, and

Hemodialysis International 2017; 21:90–96

Bone alkaline phosphatase in ESRD

3

4

5

6

7

8

9

10

11

12
13

14

15
16

treatment of chronic kidney disease-mineral and bone
disorder (CKD-MBD). Kidney Int Suppl 2009: S1–S130.
Sardiwal S, Gardham C, Coleman AE, Stevens PE,
Delaney MP, Lamb EJ. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients.
Kidney Int 2012; 82:100–105.
Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH—
A particularly tricky hormone: Why measure it at all
in kidney patients? Clin J Am Soc Nephrol 2013; 8:
299–312.
Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul
MC. Plasma total versus bone alkaline phosphatase as
markers of bone turnover in hemodialysis patients.
J Am Soc Nephrol 1996; 7:506–512.
Malluche HH, Mawad HW, Monier-Faugere MC. Renal
osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and
white patients. J Bone Miner Res 2011; 26:1368–1376.
Adragao T, Herberth J, Monier-Faugere MC, et al. Low
bone volume—A risk factor for coronary calcifications
in hemodialysis patients. Clin J Am Soc Nephrol 2009;
4:450–455.
Coco M, Rush H. Increased incidence of hip fractures
in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115–1121.
Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M,
et al., Asturias Study Group. Vascular calcifications,
vertebral fractures and mortality in haemodialysis
patients. Nephrol Dial Transplant 2009; 24:239–246.
Sawaya BP, Butros R, Naqvi S, et al. Differences in
bone turnover and intact PTH levels between African
American and Caucasian patients with end-stage renal
disease. Kidney Int 2003; 64:737–742.
Moore C, Yee J, Malluche H, et al. Relationship
between bone histology and markers of bone and mineral metabolism in African-American hemodialysis
patients. Clin J Am Soc Nephrol 2009; 4:1484–1493.
Malluche HH, Faugere M-C. Atlas of mineralized bone
histology, 1986.
Breiman L, Friedman J, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, CA: Wadsworth
International Group, 1984.
Fedde KN, Lane CC, Whyte MP. Alkaline phosphatase
is an ectoenzyme that acts on micromolar concentrations of natural substrates at physiologic pH in human
osteosarcoma (SAOS-2) cells. Arch Biochem Biophys
1988; 264:400–409.
Hooper NM. Glycosyl-phosphatidylinositol anchored
membrane enzymes. Int J Clin Chem 1997; 266:3–12.
Anh DJ, Dimai HP, Hall SL, Farley JR. Skeletal alkaline
phosphatase activity is primarily released from human
osteoblasts in an insoluble form, and the net release is
inhibited by calcium and skeletal growth factors. Calcified Tissue Int 1998; 62:332–340.

Hemodialysis International 2017; 21:90–96

17 Anh DJ, Eden A, Farley JR. Quantitation of soluble
and skeletal alkaline phosphatase, and insoluble alkaline phosphatase anchor-hydrolase activities in human
serum. Int J Clin Chem 2001; 311:137–148.
18 Blom E, Ali MM, Mortensen B, Huseby NE. Elimination of alkaline phosphatases from circulation by the
galactose receptor. Different isoforms are cleared at
various rates. Int J Clin Chem 1998; 270:125–137.
19 Posen S, Grunstein HS. Turnover rate of skeletal alkaline phosphatase in humans. Clin Chem 1982; 28:153–
154.
20 Walton RJ, Preston CJ, Russell RG, Kanis JA. An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget’s disease. Clin Chim Acta
1975; 63:227–229.
21 Moss DW, Whitby LG. A simplified heat-inactivation
method for investigating alkaline phosphatase isoenzymes in serum. Clin Chim Acta 1975; 61:63–71.
22 Rosalki SB, Foo AY. Two new methods for separating
and quantifying bone and liver alkaline phosphatase
isoenzymes in plasma. Clin Chem 1984; 30:1182–
1186.
23 Griffiths J, Black J. Separation and identification of
alkaline phosphatase isoenzymes and isoforms in
serum of healthy persons by isoelectric focusing. Clin
Chem 1987; 33:2171–2177.
24 Broyles DL, Nielsen RG, Bussett EM, et al. Analytical
and clinical performance characteristics of Tandem-MP
Ostase, a new immunoassay for serum bone alkaline
phosphatase. Clin Chem 1998; 44:2139–2147.
25 Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995; 41:1560–
1566.
26 Hill CS, Wolfert RL. The preparation of monoclonal
antibodies which react preferentially with human bone
alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1990; 186:315–320.
27 Panigrahi K, Delmas PD, Singer F, et al. Characteristics
of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994;
40:822–828.
28 Martin M, Van Hoof V, Couttenye M, et al. Analytical
and clinical evaluation of a method to quantify bone
alkaline phosphatase, a marker of osteoblastic activity.
Anticancer Res 1997; 17:3167–3170.
29 Urena P, De Vernejoul MC. Circulating biochemical
markers of bone remodeling in uremic patients. Kidney
Int 1999; 55:2141–2156.
30 Magnusson P, Larsson L, Magnusson M, Davie MW,
Sharp CA. Isoforms of bone alkaline phosphatase:
characterization and origin in human trabecular and
cortical bone. J Bone Miner Res 1999; 14:1926–1933.
31 Iimori S, Mori Y, Akita W, et al. Diagnostic usefulness
of bone mineral density and biochemical markers of

95

Yessayan et al.

32

33

34

35

36

96

bone turnover in predicting fracture in CKD stage 5D
patients—A single-center cohort study. Nephrol, Dial,
Transplant 2012; 27:345–351.
Drechsler C, Verduijn M, Pilz S, et al. Bone alkaline
phosphatase and mortality in dialysis patients. Clin J
Am Soc Nephrol 2011; 6:1752–1759.
Kobayashi I, Shidara K, Okuno S, et al. Higher serum
bone alkaline phosphatase as a predictor of mortality in
male hemodialysis patients. Life Sci 2012; 90:212–218.
Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High
alkaline phosphatase levels in hemodialysis patients are
associated with higher risk of hospitalization and
death. Kidney Int 2008; 74:655–663.
Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum
alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;
19:2193–2203.
Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone
disease in maintenance hemodialysis patients. Kidney
Int 2006; 70:771–780.

37 Shantouf R, Kovesdy CP, Kim Y, et al. Association of
serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J
Am Soc Nephrol 2009; 4:1106–1114.
38 Couttenye MM, D’Haese PC, Van Hoof VO,
Lemoniatou E, Goodman W, Verpooten GA, De Broe
ME. Low serum levels of alkaline phosphatase of bone
origin: A good marker of adynamic bone disease in
haemodialysis patients. Nephrol, Dial, Transplant 1996;
11:1065–1072.
39 Jarava C, Armas JR, Salgueira M, Palma A. Bone alkaline phosphatase isoenzyme in renal osteodystrophy.
Nephrol, Dial, Transplant 1996; 11(Suppl 3):43–46.
40 Fletcher S, Jones RG, Rayner HC, et al. Assessment of
renal osteodystrophy in dialysis patients: use of bone
alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology.
Nephron 1997; 75:412–419.
41 London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage
renal disease. J Am Soc Nephrol 2004; 15:1943–1951.

Hemodialysis International 2017; 21:90–96

